Aptahem
Manufacturing · Sweden · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Norra Vallgatan 58, Malmoe, Skane, 211 2...Phone Number
+46 766333699Website
www.aptahem.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Aptahem
Aptahem is a biotechnology company focused on developing RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions, particularly sepsis and other acute inflammatory diseases. Their lead candidate, Apta-1, is currently in early clinical phases and aims to address the significant global medical need for effective treatments for sepsis, which affects millions annually. The company utilizes synthetic aptamers, which are alternatives to antibodies, to create disruptive treatments with low immunogenicity. Aptahem's target clients include healthcare providers and institutions dealing with critical care and sepsis management.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aptahem your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Aptahem has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Aptahem
Funding: Get notified immidiatlly once Aptahem has new funding data
Product Launch: Get notified when Aptahem launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Aptahem recently announced quarterly report
Click to see if Aptahem had a recent Job posting/layoffs
Aptahem, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if Aptahem is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Aptahem as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Aptahem is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Aptahem is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Aptahem.
Aptahem Tech Stack
A closer look at the technologies used by Aptahem
Most Recent Scoops
Project
Intellectual Property, Legal Affairs, Pharmaceuticals
New Hire
Executive Move
Left Company
Executive Move
Left Company
Executive Move
Aptahem News & Media
Aptahem's Scientific Collaboration on Apta-1’s Mechanism of Action Accepted for Publication in the British Journal of Pharmacology
Aptahem announced today that their scientific collaboration with Örebro University has led to a groundbreaking manuscript, which has been accepted for publication in the prestigious British Journal of Pharmacology (BJP). BJP is one of the highest-ranked scientific journals globally, placing in the top 5th percentile with an impact factor of approximately 7. This recognition underscores the importance of Aptahem's development research and its potential contribution to pharmacological science. TheAptahem comments on interesting data after finalised phase 1 study
Aptahem AB (publ), a biotechnology company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, today announced that the completed double-blind randomised placebo-controlled phase 1 study in healthy volunteers also showed indications of drug efficacy. 1. Aptahem has summarised and concluded all additional analyses taking into account the recently completed phase 1 study. 2. At dosing, interesting immunological marker responses were noted in the subjects,Aptahem receives patent protection in Israel for patent family 2
Aptahem AB (publ) announces today that the company has received patent protection in Israel for patent family 2 from the Israeli Patent Office. With the approval in Israel of patent application 273759, the protection of the company’s drug candidate Apta-1 within patent family 2 in Israel, Israeli Patent No. 273759, is valid until the end of 2038. For further information: Aptahem AB Mikael Lindstam, CEO Tel: +46 (0)766-33 36 99 E-mail: ml@aptahem.com About Aptahem AptahemAptahem reports the FIH study on Apta-1 has been finalized
Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, today announces that the report on the First in Human (FIH) study has been finalized. The final study report confirms the previous top line results. The study is now closed and reported to the authorities. The top line results previously communicated from the study shows that Apta-1 has been well tolerated in the given doses. No serious
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Aptahem
Sign Up For FreeTo access detailed company insights
Aptahem is a biotechnology company focused on developing RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions, particularly sepsis and other acute inflammatory diseases. Their lead candidate, Apta-1, is currently in early clinical phases and aims to address the significant global medical need for effective treatments fo... Read More
